Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug , for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.